PD-1, PD-L1, and CTLA-4 inhibitors display encouraging therapeutic effects among common ICIs, some of which have been ratified to treat melanoma, non-small-cell lung cancer, kidney cancer, and bladder cancer [54–56]. Here, CTLA4 is linked to urinary bladder cancer.